Recently, a study found that colorectal cancer patients with positive expression of ETV5, a member of the ETS transcription factor family that can trigger angiogenesis by upregulating VEGFA, are resistant to bevacizumab [29]. The gene discussed is ETV5; the disease is colorectal cancer.